

Covid-19 Impact on Pulmonary Drugs Market, Global Research Reports 2020-2021

https://marketpublishers.com/r/C99AB4339C22EN.html

Date: June 2020

Pages: 90

Price: US\$ 3,250.00 (Single User License)

ID: C99AB4339C22EN

Abstracts

This report covers market size and forecasts of Pulmonary Drugs, including the following market information:

Global Pulmonary Drugs Market Size, 2019-2021, and 2020 (quarterly data), (US\$ Million) & (K Units)

Global Pulmonary Drugs Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US\$ Million) & (K Units)

Global Pulmonary Drugs Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US\$ Million) & (K Units)

Global Pulmonary Drugs Market Size by Company, 2019- 2020 (quarterly data), (US\$ Million) & (K Units)

Key market players

Major competitors identified in this market include Sanofi SA, Meda Pharmaceuticals, Circassia Pharmaceuticals Plc., AstraZeneca Plc., GlaxoSmithKline Plc., Mallinckrodt Pharmaceuticals Plc., Cheisi Farmaceutici S.p.A, Zambon Company S.p.A, Alaxia SAS, Merck Sharp & Dohme Limited, etc.

Based on the Region:

Asia-Pacific (China, Japan, South Korea, India and ASEAN)



North America (US and Canada)
Europe (Germany, France, UK and Italy)
Rest of World (Latin America, Middle East & Africa)
Based on the Type:
Inhaled Corticosteroids
Long Acting Beta-2 Agonists
Antihistamines
Vasodilators
Others
Based on the Application:
Asthma & COPD
Allergic Rhinitis
Pulmonary Arterial Hypertension
Cystic Fibrosis
Others



Contents

- 1.1 Research Scope
- 1.2 Market Segmentation
- 1.3 Research Objectives
- 1.4 Research Methodology
 - 1.4.1 Research Process
 - 1.4.2 Data Triangulation
 - 1.4.3 Research Approach
 - 1.4.4 Base Year
- 1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
 - 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
 - 1.5.2 Covid-19 Impact: Commodity Prices Indices
 - 1.5.3 Covid-19 Impact: Global Major Government Policy
- 1.6 The Covid-19 Impact on Pulmonary Drugs Industry
- 1.7 COVID-19 Impact: Pulmonary Drugs Market Trends

2 GLOBAL PULMONARY DRUGS QUARTERLY MARKET SIZE ANALYSIS

- 2.1 Pulmonary Drugs Business Impact Assessment COVID-19
- 2.1.1 Global Pulmonary Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
- 2.1.2 Global Pulmonary Drugs Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
- 2.2 Global Pulmonary Drugs Quarterly Market Size 2020-2021
- 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
 - 2.3.1 Drivers
 - 2.3.2 Restraints
 - 2.3.3 Opportunities
 - 2.3.4 Challenges

3 QUARTERLY COMPETITIVE ASSESSMENT, 2020

- 3.1 Global Pulmonary Drugs Quarterly Market Size by Manufacturers, 2019 VS 2020
- 3.2 Global Pulmonary Drugs Factory Price by Manufacturers
- 3.3 Location of Key Manufacturers Pulmonary Drugs Manufacturing Factories and Area Served
- 3.4 Date of Key Manufacturers Enter into Pulmonary Drugs Market



- 3.5 Key Manufacturers Pulmonary Drugs Product Offered
- 3.6 Mergers & Acquisitions, Expansion Plans

4 IMPACT OF COVID-19 ON PULMONARY DRUGS SEGMENTS, BY TYPE

- 4.1 Introduction
 - 1.4.1 Inhaled Corticosteroids
 - 1.4.2 Long Acting Beta-2 Agonists
 - 1.4.3 Antihistamines
 - 1.4.4 Vasodilators
 - 1.4.5 Others
- 4.2 By Type, Global Pulmonary Drugs Market Size, 2019-2021
 - 4.2.1 By Type, Global Pulmonary Drugs Market Size by Type, 2020-2021
 - 4.2.2 By Type, Global Pulmonary Drugs Price, 2020-2021

5 IMPACT OF COVID-19 ON PULMONARY DRUGS SEGMENTS, BY APPLICATION

- 5.1 Overview
 - 5.5.1 Asthma & COPD
 - 5.5.2 Allergic Rhinitis
 - 5.5.3 Pulmonary Arterial Hypertension
 - 5.5.4 Cystic Fibrosis
 - 5.5.5 Others
- 5.2 By Application, Global Pulmonary Drugs Market Size, 2019-2021
 - 5.2.1 By Application, Global Pulmonary Drugs Market Size by Application, 2019-2021
 - 5.2.2 By Application, Global Pulmonary Drugs Price, 2020-2021

6 GEOGRAPHIC ANALYSIS

- 6.1 Introduction
- 6.2 North America
 - 6.2.1 Macroeconomic Indicators of US
 - 6.2.2 US
 - 6.2.3 Canada
- 6.3 Europe
 - 6.3.1 Macroeconomic Indicators of Europe
 - 6.3.2 Germany
 - 6.3.3 France
 - 6.3.4 UK



- 6.3.5 Italy
- 6.4 Asia-Pacific
 - 6.4.1 Macroeconomic Indicators of Asia-Pacific
 - 6.4.2 China
 - 6.4.3 Japan
 - 6.4.4 South Korea
 - 6.4.5 India
 - 6.4.6 ASEAN
- 6.5 Rest of World
 - 6.5.1 Latin America
 - 6.5.2 Middle East and Africa

7 COMPANY PROFILES

- 7.1 Sanofi SA
 - 7.1.1 Sanofi SA Business Overview
 - 7.1.2 Sanofi SA Pulmonary Drugs Quarterly Production and Revenue, 2020
 - 7.1.3 Sanofi SA Pulmonary Drugs Product Introduction
 - 7.1.4 Sanofi SA Response to COVID-19 and Related Developments
- 7.2 Meda Pharmaceuticals
 - 7.2.1 Meda Pharmaceuticals Business Overview
- 7.2.2 Meda Pharmaceuticals Pulmonary Drugs Quarterly Production and Revenue, 2020
 - 7.2.3 Meda Pharmaceuticals Pulmonary Drugs Product Introduction
 - 7.2.4 Meda Pharmaceuticals Response to COVID-19 and Related Developments
- 7.3 Circassia Pharmaceuticals Plc.
 - 7.3.1 Circassia Pharmaceuticals Plc. Business Overview
- 7.3.2 Circassia Pharmaceuticals Plc. Pulmonary Drugs Quarterly Production and Revenue, 2020
- 7.3.3 Circassia Pharmaceuticals Plc. Pulmonary Drugs Product Introduction
- 7.3.4 Circassia Pharmaceuticals Plc. Response to COVID-19 and Related Developments
- 7.4 AstraZeneca Plc.
 - 7.4.1 AstraZeneca Plc. Business Overview
 - 7.4.2 AstraZeneca Plc. Pulmonary Drugs Quarterly Production and Revenue, 2020
 - 7.4.3 AstraZeneca Plc. Pulmonary Drugs Product Introduction
 - 7.4.4 AstraZeneca Plc. Response to COVID-19 and Related Developments
- 7.5 GlaxoSmithKline Plc.
- 7.5.1 GlaxoSmithKline Plc. Business Overview



- 7.5.2 GlaxoSmithKline Plc. Pulmonary Drugs Quarterly Production and Revenue, 2020
- 7.5.3 GlaxoSmithKline Plc. Pulmonary Drugs Product Introduction
- 7.5.4 GlaxoSmithKline Plc. Response to COVID-19 and Related Developments
- 7.6 Mallinckrodt Pharmaceuticals Plc.
- 7.6.1 Mallinckrodt Pharmaceuticals Plc. Business Overview
- 7.6.2 Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Quarterly Production and Revenue, 2020
 - 7.6.3 Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Product Introduction
- 7.6.4 Mallinckrodt Pharmaceuticals Plc. Response to COVID-19 and Related Developments
- 7.7 Cheisi Farmaceutici S.p.A
 - 7.7.1 Cheisi Farmaceutici S.p.A Business Overview
- 7.7.2 Cheisi Farmaceutici S.p.A Pulmonary Drugs Quarterly Production and Revenue, 2020
 - 7.7.3 Cheisi Farmaceutici S.p.A Pulmonary Drugs Product Introduction
- 7.7.4 Cheisi Farmaceutici S.p.A Response to COVID-19 and Related Developments
- 7.8 Zambon Company S.p.A
- 7.8.1 Zambon Company S.p.A Business Overview
- 7.8.2 Zambon Company S.p.A Pulmonary Drugs Quarterly Production and Revenue, 2020
- 7.8.3 Zambon Company S.p.A Pulmonary Drugs Product Introduction
- 7.8.4 Zambon Company S.p.A Response to COVID-19 and Related Developments 7.9 Alaxia SAS
 - 7.9.1 Alaxia SAS Business Overview
 - 7.9.2 Alaxia SAS Pulmonary Drugs Quarterly Production and Revenue, 2020
 - 7.9.3 Alaxia SAS Pulmonary Drugs Product Introduction
 - 7.9.4 Alaxia SAS Response to COVID-19 and Related Developments
- 7.10 Merck Sharp & Dohme Limited
 - 7.10.1 Merck Sharp & Dohme Limited Business Overview
- 7.10.2 Merck Sharp & Dohme Limited Pulmonary Drugs Quarterly Production and Revenue, 2020
 - 7.10.3 Merck Sharp & Dohme Limited Pulmonary Drugs Product Introduction
- 7.10.4 Merck Sharp & Dohme Limited Response to COVID-19 and Related Developments

8 SUPPLY CHAIN AND SALES CHANNELS ANALYSIS

- 8.1 Pulmonary Drugs Supply Chain Analysis
 - 8.1.1 Pulmonary Drugs Supply Chain Analysis



- 8.1.2 Covid-19 Impact on Pulmonary Drugs Supply Chain
- 8.2 Distribution Channels Analysis
 - 8.2.1 Pulmonary Drugs Distribution Channels
 - 8.2.2 Covid-19 Impact on Pulmonary Drugs Distribution Channels
 - 8.2.3 Pulmonary Drugs Distributors
- 8.3 Pulmonary Drugs Customers

9 KEY FINDINGS

10 APPENDIX

- 10.1 About Us
- 10.2 Disclaimer



List Of Tables

LIST OF TABLES

- Table 1. Overview of the World Economic Outlook Projections
- Table 2. Summary of World Real per Capita Output (Annual percent change; in international currency at purchasing power parity)
- Table 3. European Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
- Table 4. Asian and Pacific Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
- Table 5. Western Hemisphere Economies: Real GDP, Consumer Prices, Current
- Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
- Table 6. Middle Eastern and Central Asian Economies: Real GDP, Consumer Prices,
- Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
- Table 7. Covid-19 Impact: Global Major Government Policy
- Table 8. The Covid-19 Impact on Pulmonary Drugs Assessment
- Table 9. COVID-19 Impact: Pulmonary Drugs Market Trends
- Table 10. COVID-19 Impact Global Pulmonary Drugs Market Size
- Table 11. Global Pulmonary Drugs Market Size Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 (K Units)
- Table 12. Global Pulmonary Drugs Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026, (USD/Unit)
- Table 13. Global Pulmonary Drugs Quarterly Market Size, 2020 (US\$ Million) & (K Units)
- Table 14. Global Pulmonary Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Quarterly Comparison, 2020-2021 (US\$ Million)
- Table 15. Global Pulmonary Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Quarterly Comparison, 2020-2021 (K Units)
- Table 16. Global Pulmonary Drugs Market Growth Drivers
- Table 17. Global Pulmonary Drugs Market Restraints
- Table 18. Global Pulmonary Drugs Market Opportunities
- Table 19. Global Pulmonary Drugs Market Challenges
- Table 20. Key Manufacturers Pulmonary Drugs Quarterly Revenue, 2019 VS 2020 (US\$ Million)
- Table 21. Top Manufacturers, Pulmonary Drugs Market Size, 2019 (K Units) & (US\$ Million)
- Table 22. Pulmonary Drugs Factory Price by Manufacturers 2020 (USD/Unit)



- Table 23. Location of Key Manufacturers Pulmonary Drugs Manufacturing Plants
- Table 24. Key Manufacturers Pulmonary Drugs Market Served
- Table 25. Date of Key Manufacturers Enter into Pulmonary Drugs Market
- Table 26. Key Manufacturers Pulmonary Drugs Product Type
- Table 27. Mergers & Acquisitions, Expansion Plans
- Table 28. Global Pulmonary Drugs Market Size by Type, 2020, (US\$ Million)
- Table 29. Global Pulmonary Drugs Market Size by Type, 2020 (K Units)
- Table 30. Global Pulmonary Drugs Price: by Type, 2020-2021 (USD/Unit)
- Table 31. Global Pulmonary Drugs Market Size by Application: 2020-2021 (US\$ Million)
- Table 32. Global Pulmonary Drugs Market Size by Application, 2020-2021 (K Units)
- Table 33. Global Pulmonary Drugs Price: by Application, 2020-2021 (USD/Unit)
- Table 34. Global Pulmonary Drugs Market Size by Region, 2019-2021 (US\$ Million)
- Table 35. Global Pulmonary Drugs Market Size by Region, 2019-2021 (K Units)
- Table 36. By Country, North America Pulmonary Drugs Market Size, 2019-2021 (US\$ Million)
- Table 37. By Country, North America Pulmonary Drugs Market Size, 2019-2021 (K Units)
- Table 38. US Pulmonary Drugs Market Size, 2019-2021 (US\$ Million) & (K Units)
- Table 39. Canada Pulmonary Drugs Market Size, 2019-2021 (US\$ Million) & (K Units)
- Table 40. Macroeconomic Indicators of Europe (Germany, France, UK and Italy)
- Table 41. By Country, Europe Pulmonary Drugs Market Size, 2019-2021 (US\$ Million)
- Table 42. By Country, Europe Pulmonary Drugs Market Size, 2019-2021 (K Units)
- Table 43. Germany Pulmonary Drugs Market Size, 2019-2021 (US\$ Million) & (K Units)
- Table 44. France Pulmonary Drugs Market Size, 2019-2021 (US\$ Million) & (K Units)
- Table 45. UK Pulmonary Drugs Market Size, 2019-2021 (US\$ Million) & (K Units)
- Table 46. Italy Pulmonary Drugs Market Size, 2019-2021 (US\$ Million) & (K Units)
- Table 47. Macroeconomic Indicators of Asia-Pacific (China, Japan, South Korea, India and ASEAN)
- Table 48. By Region, Asia-Pacific Pulmonary Drugs Market Size, 2019-2021 (US\$ Million)
- Table 49. By Region, Asia-Pacific Pulmonary Drugs Market Size, 2019-2021 (K Units)
- Table 50. China Pulmonary Drugs Market Size, 2019-2021 (US\$ Million) & (K Units)
- Table 51. Japan Pulmonary Drugs Market Size, 2019-2021 (US\$ Million) & (K Units)
- Table 52. South Korea Pulmonary Drugs Market Size, 2019-2021 (US\$ Million) & (K Units)
- Table 53. India Pulmonary Drugs Market Size, 2019-2021 (US\$ Million) & (K Units)
- Table 54. ASEAN Pulmonary Drugs Market Size, 2019-2021 (US\$ Million) & (K Units)
- Table 55. Latin America Pulmonary Drugs Market Size, 2019-2021 (US\$ Million) & (K Units)



- Table 56. Middle East and Africa Pulmonary Drugs Market Size, 2019-2021 (US\$
- Million) & (K Units)
- Table 57. Sanofi SA Business Overview
- Table 58. Sanofi SA Pulmonary Drugs Production (K Units), Revenue (US\$ Million),
- Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
- Table 59. Sanofi SA Pulmonary Drugs Product
- Table 60. Sanofi SA Response to COVID-19 and Related Developments
- Table 61. Meda Pharmaceuticals Business Overview
- Table 62. Meda Pharmaceuticals Pulmonary Drugs Production (K Units), Revenue (US\$
- Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
- Table 63. Meda Pharmaceuticals Pulmonary Drugs Product
- Table 64. Meda Pharmaceuticals Response to COVID-19 and Related Developments
- Table 65. Circassia Pharmaceuticals Plc. Business Overview
- Table 66. Circassia Pharmaceuticals Plc. Pulmonary Drugs Production (K Units),
- Revenue (US\$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
- Table 67. Circassia Pharmaceuticals Plc. Pulmonary Drugs Product
- Table 68. Circassia Pharmaceuticals Plc. Response to COVID-19 and Related Developments
- Table 69. AstraZeneca Plc. Business Overview
- Table 70. AstraZeneca Plc. Pulmonary Drugs Production (K Units), Revenue (US\$
- Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
- Table 71. AstraZeneca Plc. Pulmonary Drugs Product
- Table 72. AstraZeneca Plc. Response to COVID-19 and Related Developments
- Table 73. GlaxoSmithKline Plc. Business Overview
- Table 74. GlaxoSmithKline Plc. Pulmonary Drugs Production (K Units), Revenue (US\$
- Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
- Table 75. GlaxoSmithKline Plc. Pulmonary Drugs Product
- Table 76. GlaxoSmithKline Plc. Response to COVID-19 and Related Developments
- Table 77. Mallinckrodt Pharmaceuticals Plc. Business Overview
- Table 78. Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Production (K Units),
- Revenue (US\$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
- Table 79. Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Product
- Table 80. Mallinckrodt Pharmaceuticals Plc. Response to COVID-19 and Related Developments
- Table 81. Cheisi Farmaceutici S.p.A Business Overview
- Table 82. Cheisi Farmaceutici S.p.A Pulmonary Drugs Production (K Units), Revenue
- (US\$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020



Table 83. Cheisi Farmaceutici S.p.A Pulmonary Drugs Product

Table 84. Cheisi Farmaceutici S.p.A Response to COVID-19 and Related

Developments

Table 85. Zambon Company S.p.A Business Overview

Table 86. Zambon Company S.p.A Pulmonary Drugs Production (K Units), Revenue

(US\$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 87. Zambon Company S.p.A Pulmonary Drugs Product

Table 88. Zambon Company S.p.A Response to COVID-19 and Related Developments

Table 89. Alaxia SAS Business Overview

Table 90. Alaxia SAS Pulmonary Drugs Production (K Units), Revenue (US\$ Million),

Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 91. Alaxia SAS Pulmonary Drugs Product

Table 92. Alaxia SAS Response to COVID-19 and Related Developments

Table 93. Merck Sharp & Dohme Limited Business Overview

Table 94. Merck Sharp & Dohme Limited Pulmonary Drugs Production (K Units),

Revenue (US\$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 95. Merck Sharp & Dohme Limited Pulmonary Drugs Product

Table 96. Merck Sharp & Dohme Limited Response to COVID-19 and Related

Developments

Table 97. Pulmonary Drugs Distributors List

Table 98. Pulmonary Drugs Customers List

Table 99. Covid-19 Impact on Pulmonary Drugs Customers



List Of Figures

LIST OF FIGURES

- Figure 1. Pulmonary Drugs Product Picture
- Figure 2. Pulmonary Drugs Market Segmentation
- Figure 3. Research Objectives
- Figure 4. Research Process
- Figure 5. Data Triangulation
- Figure 6. Research Approach
- Figure 7. Commodity Prices-Metals Price Indices
- Figure 8. Commodity Prices- Precious Metal Price Indices
- Figure 9. Commodity Prices- Agricultural Raw Material Price Indices
- Figure 10. Commodity Prices- Food and Beverage Price Indices
- Figure 11. Commodity Prices- Fertilizer Price Indices
- Figure 12. Commodity Prices- Energy Price Indices
- Figure 13. G20+: Economic Policy Responses to COVID-19
- Figure 14. Global Pulmonary Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 (US\$ Million)
- Figure 15. Global Pulmonary Drugs Market Size, Pre-COVID-19 and Post- COVID-19, Year-over-Year Growth Rate, 2015-2026 (%)
- Figure 16. Global Pulmonary Drugs Market Size, Quarterly Growth, 2020-2021 (%)
- Figure 17. Global Pulmonary Drugs Market Size, Market Share by Type, 2019 VS 2020 (%)
- Figure 18. Global Pulmonary Drugs Market Size, Market Share by Application, 2019 VS 2020 (%)
- Figure 19. Global Pulmonary Drugs Market Size Market Share by Region, 2019 VS 2020 (%)
- Figure 20. United States Composite PMI and GDP
- Figure 21. Eurozone Composite PMI and GDP
- Figure 22. Eurozone Core v. Periphery PMI Output Indices
- Figure 23. Core v. Periphery PMI Employment Indices
- Figure 24. UK Composite PMI and GDP
- Figure 25. Caixin China Composite Output Index
- Figure 26. Caixin China General Services Business Activity Index
- Figure 27. Japan Composite Output Index
- Figure 28. South Korea Manufacturing PMI
- Figure 29. India Composite Output Index
- Figure 30. ASEAN Manufacturing PMI



Figure 31. By Region, Asia-Pacific Pulmonary Drugs Market Size Market Share, 2019-2021



I would like to order

Product name: Covid-19 Impact on Pulmonary Drugs Market, Global Research Reports 2020-2021

Product link: https://marketpublishers.com/r/C99AB4339C22EN.html

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/C99AB4339C22EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970